Preoperative platelet‑lymphocyte ratio is an independent prognostic factor in ampullary carcinoma following pancreaticoduodenectomy

Abstract Purpose Platelet-to-lymphocyte ratio (PLR) was established showing the poor prognosis in several diseases, such as malignancies and cardiovascular diseases. But limited study has been conducted about the prognostic value of PLR on the long-term renal survival of patients with Immunoglobulin A nephropathy (IgAN). Methods We performed an observational cohort study enrolling patients with biopsy-proven IgAN recorded from November 2011 to March 2016. The definition of composite endpoint was eGFR decrease by 50%, eGFR < 15 mL/min/1.73 m2, initiation of dialysis, or renal transplantation. Patients were categorized by the magnitude of PLR tertiles into three groups. The Kaplan–Meier curves and multivariate Cox models were performed to determine the association of PLR with the renal survival of IgAN patients. Results 330 patients with a median age of 34.0 years were followed for a median of 47.4 months, and 27 patients (8.2%) had reached the composite endpoints. There were no differences among the three groups (PLR < 106, 106 ≤ PLR ≤ 137, and PLR > 137) in demographic characteristics, mean arterial pressure (MAP), proteinuria, and estimated glomerular filtration rate (eGFR) at baseline. The Kaplan–Meier curves showed that the PLR > 137 group was significantly more likely to poor renal outcomes than the other two groups. Using univariate and multivariate cox regression analyses, we found that PLR > 137 was an independent prognostic factor for poor renal survival in patients with IgAN. Subgroup analysis revealed that the PLR remained the prognostic value for female patients or patients with eGFR less than 60 mL/min/1.73 m2. Conclusions Our results underscored that baseline PLR was an independent prognostic factor for poor renal survival in patients with IgAN, especially for female patients or those patients with baseline eGFR less than 60 mL/min/1.73 m2.

Download Full-text

High Expression of Telomerase is an Independent Prognostic Factor in Ampullary Carcinoma

Gastroenterology ◽

10.1016/s0016-5085(11)64203-0 ◽

2011 ◽

Vol 140 (5) ◽

pp. S-1012

Author(s):

Ryutaro Sakabe ◽

Yoshiaki Murakami ◽

Kenichiro Uemura ◽

Takeshi Sudo ◽

Yasushi Hashimoto ◽

...

Keyword(s):

Prognostic Factor ◽

Ampullary Carcinoma ◽

Independent Prognostic Factor ◽

High Expression

Download Full-text

The (Neutrophils + Monocyte)/Lymphocyte Ratio Is an Independent Prognostic Factor for Progression-Free Survival in Newly Diagnosed Multiple Myeloma Patients Treated With BCD Regimen

Frontiers in Oncology ◽

10.3389/fonc.2020.01617 ◽

2020 ◽

Vol 10 ◽

Author(s):

Yanbin Pang ◽

Hong Shao ◽

Ziheng Yang ◽

Lixia Fan ◽

Wenwen Liu ◽

...

Keyword(s):

Multiple Myeloma ◽

Prognostic Factor ◽

Progression Free Survival ◽

Independent Prognostic Factor ◽

Newly Diagnosed ◽

Free Survival ◽

Lymphocyte Ratio

Download Full-text

The comparison of thrombocytosis and platelet-lymphocyte ratio as potential prognostic markers in colorectal cancer

Thrombosis and Haemostasis ◽

10.1160/th13-08-0632 ◽

2014 ◽

Vol 111 (03) ◽

pp. 483-490 ◽

Cited By ~ 35

Author(s):

Valéria Jósa ◽

Kristóf Dede ◽

Emese Ágoston ◽

Marcell Szász ◽

Dániel Sinkó ◽

...

Keyword(s):

Colorectal Cancer ◽

Multivariate Analysis ◽

Platelet Count ◽

Prognostic Factor ◽

Prognostic Markers ◽

Disease Free Survival ◽

Free Survival ◽

Lymphocyte Ratio ◽

Platelet Lymphocyte Ratio ◽

Disease Free

SummaryThe aim of the present study was to analyse the preoperative platelet count and the platelet-lymphocyte ratio (PLR) in patients with colorectal cancer (CRC) of different stages and with hepatic metastasis of CRC (mCRC) and to compare these factors as potential prognostic markers. Clinicopathological data of 10 years were collected retrospectively from 336 patients with CRC and 118 patients with mCRC. Both in the CRC and the mCRC group overall survival (OS) was significantly worse in patients who had elevated platelet count (hazard ratio [HR] = 2.2, p < 0.001 and HR = 2.9, p = 0.018, respectively). Multivariate analysis indicated that elevated platelet count was an independent prognostic factor of CRC (HR = 1.7, p = 0.035) and mCRC (HR = 3.1, p = 0.017). Disease-free survival (DFS) was significantly worse in patients with elevated platelet count in the CRC group (HR = 2.0, p = 0.011). In the multivariate analysis the PLR was not a prognostic factor in either of the two cohorts (HR = 0.92, p < 0.001 and HR = 0.89, p = 0.789, respectively). The platelet count is a valuable prognostic marker for the survival in patients both with CRC and mCRC while the PLR is not prognostic in either group.

Download Full-text

S268 Neutrophil to lymphocyte ratio as an independent prognostic factor in nonmetastatic renal cell carcinoma

European Urology Supplements ◽

10.1016/s1569-9056(13)62301-5 ◽

2013 ◽

Vol 12 (4) ◽

pp. e1376, S268a-e1376, S268b

Author(s):

N. Grivas ◽

V. Kafarakis ◽

I. Tsimaris ◽

S. Aspiotis ◽

A. Stratis ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Prognostic Factor ◽

Cell Carcinoma ◽

Renal Cell ◽

Independent Prognostic Factor ◽

Neutrophil To Lymphocyte Ratio ◽

Lymphocyte Ratio

Download Full-text

Preoperative Serum Platelet-Lymphocyte Ratio as a Prognostic Factor in Cholangiocarcinoma Patients after Radical Resection: A Retrospective Analysis of 119 Patients

Gastroenterology Research and Practice ◽

10.1155/2019/8506967 ◽

2019 ◽

Vol 2019 ◽

pp. 1-9

Author(s):

Ying Wu ◽

Danyang Zhou ◽

Guoping Zhang ◽

Fengming Yi ◽

Long Feng

Keyword(s):

Prognostic Factor ◽

Adjuvant Therapy ◽

Prognostic Value ◽

Surgical Margin ◽

Progression Free Survival ◽

Radical Resection ◽

Positive Surgical Margin ◽

Lymphocyte Ratio ◽

Platelet Lymphocyte Ratio ◽

Preoperative Serum

Aims. Although prognostic markers are important to establish therapeutic strategies in patients for conducting radical resection of cholangiocarcinoma (CCA), there is still a lack of simple, valid, and repeatable markers in clinical settings. We aim to evaluate the prognostic value of the preoperative serum platelet-lymphocyte ratio (PLR) in CCA patients who underwent radical resection. Methods. We retrospectively analyzed CCA patients who underwent radical resection surgery in our institution from January 2011 to June 2016. Baseline PLR and other clinical pathological data were measured when patients were diagnosed initially. The prognostic value of PLR in overall survival (OS) and progression-free survival (PFS) were analyzed with the Cox proportional hazard model and the Kaplan–Meier method. Results. This study retrospectively analyzed 119 patients who underwent radical resection of CCA. During a median follow-up time of 11.0 months, there were 99.2% recurrences and 42.9% who died, and the median OS and PFS were 9.4 months and 7.4 months, respectively. Multivariate Cox analysis identified that elevated levels of PLR (PLR>157.25) as a significant factor predicted poorer OS (P=0.018, HR: 2.160, 95% CI: 1.139-4.096) and PFS (P=0.005, HR: 1.930, 95% CI: 1.220-3.053). In subgroup analysis, PLR also effectively predicted OS (P=0.016, HR: 2.515, 95% CI: 1.143-5.532) and PFS (P=0.042, HR: 1.908, 95% CI: 0.982-3.713) in CCA patients with positive lymphatic metastasis and/or positive surgical margin who required adjuvant therapy. Conclusions. The preoperative serum PLR is an independent prognostic factor for OS and PFS in CCA patients after radical resection, including patients requiring adjuvant therapy.

Download Full-text

TAMI-03. PROGNOSTIC SIGNIFICANCE OF NEUTROPHIL-TO-LYMPHOCYTE RATIO (NLR) IN PATIENTS WITH BRAIN METASTASES FROM DIFFERENT TUMOR ORIGINS

Neuro-Oncology ◽

10.1093/neuonc/noab196.787 ◽

2021 ◽

Vol 23 (Supplement_6) ◽

pp. vi198-vi198

Author(s):

Guanhua Deng ◽

Lei Wen ◽

zhaoming Zhou ◽

Changguo Shan ◽

Mingyao Lai ◽

...

Keyword(s):

Overall Survival ◽

Prognostic Factor ◽

Brain Metastases ◽

Median Overall Survival ◽

Cox Regression ◽

Independent Prognostic Factor ◽

Neutrophil To Lymphocyte Ratio ◽

Lymphocyte Ratio ◽

Risk Of Death ◽

Metastatic Sites

Abstract PURPOSE Brain metastases (BMs) represent the most common adult intracranial malignancy. The prognosis of BMs is subject to many factors, i.e., the number, size and locations of the metastatic sites, tumor origins, pathologic types, gene mutation status, metastatic sites, and KPS etc. This study aimed to evaluate the prognostic value of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) in brain metastases. METHODS A total of 480 patients diagnosed with brain metastases from a wide range of tumor origins, i.e., NSCLC, SCLC, breast cancer, melanoma, prostate, kidney, gastrointestinal cancer, cervical carcinoma, ovarian cancer, choriocarcinoma of uterus were retrospectively analyzed. Pre-radiotherapy NLR, PLR, and LMR were calculated as total neutrophil/lymphocyte, platelet/Lymphocyte, lymphocyte/monocyte, respectively. Survival rates were estimated using the Kaplan-Meier survival analysis. Cox regression models were used to identify independent prognostic factors. RESULTS The median overall survival (OS) was 14.4 months [95%CI: 13.4-15.5]. The median overall survival after radiotherapy was significantly different between patients with NLR< 4 and those with NLR≥4 (OS 16.3 mo. vs. 12.2 mo., P< 0.0001). No signiﬁcant difference was observed between PLR vs. OS, and LMR vs. OS (PLR< 180: HR=1.221, P=0.240; LMR< 4: HR=0.753, P=0.141). The Cox regression model for the continuous metric values revealed that the NLR increased every 1.0 was associated with additional 5.9% of fatal risk (HR: 1.059; 95%CI = 1.033–1.087, P< 0.0001). NLR was validated as an independent prognostic factor for risk of death after adjusting for sex, age, and KPS. CONCLUSIONS We revealed pre-treatment NLR is an independent prognostic factor in patients with brain metastases for poor OS, independent of different tumor origins. The NLR warrants further studies using sub-group analysis and validation in external cohorts. Future studies in this parameter have a potential to facilitate more precise risk-stratifications to guide personalized treatment for BM.

Download Full-text